Paper38780656
Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
Gurzu S and 3 others. J Cancer Res Clin Oncol, 2024. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies. Papers, record 38780656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38780656
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cholangiocarcinoma | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Bile Duct Neoplasms | Major topic |
| Humans |
Source PubMed
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30967907 | Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study. | World J Hepatol | 2019 | https://conductscience.org/library/papers/30967907 | PubMed |
| 2 | 21744084 | Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center. | J Hepatobiliary Pancreat Sci | 2012 | https://conductscience.org/library/papers/21744084 | PubMed |
| 3 | 23034166 | Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. | J Gastroenterol Hepatol | 2013 | https://conductscience.org/library/papers/23034166 | PubMed |
| 4 | 34213048 | Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study. | Oncologist | 2021 | https://conductscience.org/library/papers/34213048 | PubMed |
| 5 | 27812807 | Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. | World J Surg | 2017 | https://conductscience.org/library/papers/27812807 | PubMed |
| 6 | 18407604 | Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein. | World J Gastroenterol | 2008 | https://conductscience.org/library/papers/18407604 | PubMed |
| 7 | 23900502 | Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ιmplications for cholangiocarcinogenesis. | Int J Oncol | 2013 | https://conductscience.org/library/papers/23900502 | PubMed |
| 8 | 27320566 | Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Diagnosis and Prognosis After Resection or Transplantation. | Transplant Proc | 2016 | https://conductscience.org/library/papers/27320566 | PubMed |
| 9 | 23166536 | S100 proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma. | Hepat Mon | 2012 | https://conductscience.org/library/papers/23166536 | PubMed |
| 10 | 28765978 | Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. | Abdom Radiol (NY) | 2018 | https://conductscience.org/library/papers/28765978 | PubMed |
| 11 | 32508620 | Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection. | Case Rep Oncol | 2020 | https://conductscience.org/library/papers/32508620 | PubMed |
| 12 | 26200629 | Atypical Hepatocellular Neoplasm With Peliosis in Cirrhotic Liver Versus Hepatocellular Carcinoma: A Diagnostic Trap. | Medicine (Baltimore) | 2015 | https://conductscience.org/library/papers/26200629 | PubMed |
| 13 | 37900166 | Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37900166 | PubMed |
| 14 | 38432964 | Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab. | Intern Med | 2024 | https://conductscience.org/library/papers/38432964 | PubMed |
| 15 | 26109824 | Primary combined hepatocellular-cholangiocellular sarcoma: An unusual case. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/26109824 | PubMed |
| 16 | 2578078 | Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. | Cancer | 1985 | https://conductscience.org/library/papers/2578078 | PubMed |
| 17 | 26917546 | Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. | BMC Cancer | 2016 | https://conductscience.org/library/papers/26917546 | PubMed |
| 18 | 26496332 | Significant Shrinkage of Multifocal Liver Metastases and Long-Term Survival in a Patient With Rectal Cancer, After Trans-Arterial Chemoembolization (TACE): A Case Report. | Medicine (Baltimore) | 2015 | https://conductscience.org/library/papers/26496332 | PubMed |
| 19 | 24777610 | Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. | Liver Transpl | 2014 | https://conductscience.org/library/papers/24777610 | PubMed |
| 20 | 32173767 | Benefits of the 8th American Joint Committee on Cancer System for Hepatocellular Carcinoma Staging. | J Gastrointest Cancer | 2021 | https://conductscience.org/library/papers/32173767 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42857008 | Hepatocellular- cholangiocarcinoma collision tumor: a case report. | Front Oncol | 2026 | https://conductscience.org/library/papers/42857008 | PubMed |
| 42450313 | Programmed Death Ligand 1 (PD-L1) and Tumor-Associated Macrophages in Gastric-Type Hepatocellular Carcinoma: Prognostic Insights. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42450313 | PubMed |
| 42063578 | From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42063578 | PubMed |
| 42057824 | Long-term complete remission of metastatic combined hepatocellular-cholangiocarcinoma with nivolumab following failure of targeted therapies: a case report. | Front Oncol | 2026 | https://conductscience.org/library/papers/42057824 | PubMed |
| 41802450 | Combined hepatocellular-cholangiocarcinoma: a contemporary pathologic and molecular perspective. | J Liver Cancer | 2026 | https://conductscience.org/library/papers/41802450 | PubMed |
| 41597200 | Establishment of Patient-Derived Organoids from Hepatocellular Carcinoma: Preliminary Data on Yield, Histopathological Concordance, and Methodological Challenges. | Cells | 2026 | https://conductscience.org/library/papers/41597200 | PubMed |
| 41464759 | Outcomes of Liver Transplantation in Incidental Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma: An Exceptional Perspective from a Single-Center Experience. | J Clin Med | 2025 | https://conductscience.org/library/papers/41464759 | PubMed |
| 41037071 | Intratumoral heterogeneity of CT enhancement for component prediction and prognostic significance in combined hepatocellular carcinoma‑cholangiocarcinoma. | Eur Radiol | 2026 | https://conductscience.org/library/papers/41037071 | PubMed |
| 40843884 | Radiologic and Pathologic Insights in Combined Hepatocellular-Cholangiocarcinoma: A Report of Three Cases. | Reports (MDPI) | 2025 | https://conductscience.org/library/papers/40843884 | PubMed |
| 40502515 | Liver transplantation for combined hepatocellular cholangiocarcinoma: Current evidence, selection criteria, and therapeutic controversies. | World J Gastrointest Surg | 2025 | https://conductscience.org/library/papers/40502515 | PubMed |
| 40324881 | The rise of RAS: how gradual oncogene activation shapes the OIS spectrum. | Genes Dev | 2025 | https://conductscience.org/library/papers/40324881 | PubMed |
| 40196844 | HTRecNet: a deep learning study for efficient and accurate diagnosis of hepatocellular carcinoma and cholangiocarcinoma. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/40196844 | PubMed |
| 39948704 | Synchronous Hepatocellular and Intrahepatic Cholangiocellular Carcinoma With Predominant Ductal Plate Malformation Pattern. A Case Report and Review of the Literature. | Cancer Rep (Hoboken) | 2025 | https://conductscience.org/library/papers/39948704 | PubMed |
| 39643892 | Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39643892 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38780656
GET https://conductscience.org/api/papers/v1/38780656/references?page=2